SI1991225T1 - Uporaba deferiprona in postopki za zdravljenje in/ali preventivo friedreichove ataksije povzroäśene z intracelularno disfukcijo ĺ˝eleza - Google Patents

Uporaba deferiprona in postopki za zdravljenje in/ali preventivo friedreichove ataksije povzroäśene z intracelularno disfukcijo ĺ˝eleza

Info

Publication number
SI1991225T1
SI1991225T1 SI200731386T SI200731386T SI1991225T1 SI 1991225 T1 SI1991225 T1 SI 1991225T1 SI 200731386 T SI200731386 T SI 200731386T SI 200731386 T SI200731386 T SI 200731386T SI 1991225 T1 SI1991225 T1 SI 1991225T1
Authority
SI
Slovenia
Prior art keywords
deferiprone
treat
iron
methods
friedreich ataxia
Prior art date
Application number
SI200731386T
Other languages
English (en)
Inventor
Arnold Munnich
Michael Spino
Ioav Cabantchik
Original Assignee
Apotex Technologies Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apotex Technologies Inc. filed Critical Apotex Technologies Inc.
Publication of SI1991225T1 publication Critical patent/SI1991225T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI200731386T 2006-02-22 2007-02-21 Uporaba deferiprona in postopki za zdravljenje in/ali preventivo friedreichove ataksije povzroäśene z intracelularno disfukcijo ĺ˝eleza SI1991225T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77532006P 2006-02-22 2006-02-22
EP07701800.0A EP1991225B1 (en) 2006-02-22 2007-02-21 The use of deferiprone and methods to treat and/or prevent friedreich ataxia resulting from intracellular mishandling of iron
PCT/CA2007/000252 WO2007095728A1 (en) 2006-02-22 2007-02-21 The use of deferiprone and methods to treat and/or prevent friedreich ataxia resulting from intracellular mishandling of iron

Publications (1)

Publication Number Publication Date
SI1991225T1 true SI1991225T1 (sl) 2014-02-28

Family

ID=38436879

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200731386T SI1991225T1 (sl) 2006-02-22 2007-02-21 Uporaba deferiprona in postopki za zdravljenje in/ali preventivo friedreichove ataksije povzroäśene z intracelularno disfukcijo ĺ˝eleza

Country Status (24)

Country Link
US (3) US20090023784A1 (sl)
EP (1) EP1991225B1 (sl)
JP (1) JP5730466B2 (sl)
KR (1) KR20080104329A (sl)
CN (1) CN101420954A (sl)
AU (1) AU2007219009B2 (sl)
BR (1) BRPI0708211A2 (sl)
CA (1) CA2642778A1 (sl)
DK (1) DK1991225T3 (sl)
ES (1) ES2441065T3 (sl)
IL (1) IL193598A (sl)
MA (1) MA30266B1 (sl)
MX (1) MX2008010824A (sl)
MY (1) MY151412A (sl)
NZ (1) NZ570730A (sl)
PL (1) PL1991225T3 (sl)
PT (1) PT1991225E (sl)
RS (1) RS53225B (sl)
RU (1) RU2008137604A (sl)
SG (1) SG170020A1 (sl)
SI (1) SI1991225T1 (sl)
TN (1) TNSN08338A1 (sl)
UA (1) UA95099C2 (sl)
WO (1) WO2007095728A1 (sl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA95099C2 (ru) * 2006-02-22 2011-07-11 Арнольд Мунних Применение деферипрона при лечении железо-индуцированного повреждения митохондрий, который является следствием атаксии фридрейха
CN101679263B (zh) 2007-03-28 2014-01-15 阿普泰克斯科技公司 去铁酮的氟化衍生物
CA2722393A1 (en) * 2008-04-25 2009-10-29 Apotex Technologies Inc. Liquid formulation for deferiprone with palatable taste
MY161269A (en) * 2009-01-26 2017-04-14 Univ Pennsylvania Use of deferiprone for treatment and prevention of iron-related eye disorders
MA33985B1 (fr) 2009-07-03 2013-02-01 Apotex Technologies Inc Dérivés fluorés de 3-hydroxypyridin-4-ones
EP2456438A2 (en) 2009-07-23 2012-05-30 Novartis AG Use of azabicycloalkyl derivatives or pyrrolidine-2-one derivatives
TWI558398B (zh) 2009-09-22 2016-11-21 諾華公司 菸鹼乙醯膽鹼受體α７活化劑之用途
DK2611457T3 (da) 2010-08-30 2014-05-12 Roberto Testi Sammensætninger og fremgangsmåder til behandling af Friereichs ataxia med interferon gamma
CN102861017A (zh) * 2011-07-08 2013-01-09 辽宁省计划生育科学研究院 一种化合物在防治老年痴呆的应用
WO2013139931A1 (en) * 2012-03-21 2013-09-26 Icm (Institut Du Cerveau Et De La Moelle Épinière) Composition for use in the treatment of neurodegenerative diseases with parkinsonian syndromes
US10442779B2 (en) 2014-09-22 2019-10-15 Fratagene Therapeutics S.R.L. Compositions and methods for treating Friedreich's ataxia
US10426775B2 (en) 2017-09-11 2019-10-01 Fratagene Therapeutics Srl Methods for treating Friedreich's ataxia with etravirine
AU2018357350B2 (en) 2017-10-25 2023-09-21 Chiesi Farmaceutici S.P.A. Delayed release deferiprone tablets and methods of using the same
US12016850B2 (en) 2022-04-11 2024-06-25 Chiesi Farmaceutici S.P.A. Modified release pharmaceutical formulations comprising deferiprone
US12016851B2 (en) 2022-04-11 2024-06-25 Chiesi Farmaceutici S.P.A. Modified release pharmaceutical formulations comprising deferiprone

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5624807A (en) 1992-07-22 1997-04-29 The Mclean Hospital Corporation Methods for detecting Alzheimer's disease by measuring ratios of calcium-activated neutral protease isoforms
US6472378B2 (en) 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
US6133322A (en) * 1998-10-29 2000-10-17 Institut National De La Sante Et De La Recherche Medicale (Inserm) Quinone derivatives for treating or preventing diseases associated with iron overload
US6933104B1 (en) * 1999-04-23 2005-08-23 Shiva Biomedical, Llc Diagnosis and treatment of human kidney diseases
AUPQ262499A0 (en) * 1999-09-02 1999-09-23 University Of Queensland, The Novel iron chelators
CA2313270C (en) * 2000-06-30 2011-09-13 Apotex Inc. Use of deferiprone in treating and preventing iron-induced cardiac disease
US20040101521A1 (en) * 2002-07-12 2004-05-27 The Buck Institute For Research On Aging Iron sequestration or elimination to reduce neurodegeneration or Parkinsons disease progression
US8058442B2 (en) * 2002-11-07 2011-11-15 Technion Research And Development Foundation Ltd. Neuroprotective iron chelators and pharmaceutical compositions comprising them
US9737511B2 (en) * 2004-05-24 2017-08-22 Geoffrey C. GURTNER Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
US8829051B2 (en) * 2004-05-24 2014-09-09 Geoffrey C. GURTNER Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
US7728038B2 (en) * 2004-08-04 2010-06-01 University Of Utah Research Foundation Methods for chelation therapy
US20070197469A1 (en) * 2006-02-17 2007-08-23 Murthy Yerramilli V Fluoroquinolone carboxylic acid salt compositions
UA95099C2 (ru) * 2006-02-22 2011-07-11 Арнольд Мунних Применение деферипрона при лечении железо-индуцированного повреждения митохондрий, который является следствием атаксии фридрейха

Also Published As

Publication number Publication date
WO2007095728A1 (en) 2007-08-30
MA30266B1 (fr) 2009-03-02
AU2007219009A1 (en) 2007-08-30
KR20080104329A (ko) 2008-12-02
PL1991225T3 (pl) 2014-04-30
NZ570730A (en) 2013-05-31
DK1991225T3 (da) 2013-12-16
TNSN08338A1 (en) 2009-12-29
PT1991225E (pt) 2014-02-13
CA2642778A1 (en) 2007-08-30
UA95099C2 (ru) 2011-07-11
US20090023784A1 (en) 2009-01-22
EP1991225A1 (en) 2008-11-19
SG170020A1 (en) 2011-04-29
EP1991225B1 (en) 2013-11-06
RS53225B (en) 2014-08-29
RU2008137604A (ru) 2010-03-27
US20130190365A1 (en) 2013-07-25
AU2007219009B2 (en) 2012-12-20
US20070197649A1 (en) 2007-08-23
IL193598A (en) 2012-08-30
MX2008010824A (es) 2009-06-08
BRPI0708211A2 (pt) 2011-05-17
CN101420954A (zh) 2009-04-29
MY151412A (en) 2014-05-30
IL193598A0 (en) 2009-08-03
EP1991225A4 (en) 2009-07-29
JP2009527506A (ja) 2009-07-30
JP5730466B2 (ja) 2015-06-10
ES2441065T3 (es) 2014-01-31

Similar Documents

Publication Publication Date Title
IL193598A0 (en) The use of deferiprone and methods to treat and/or prevent friedreich ataxia resulting from intracellular mishandling of iron
IL242168A0 (en) Activin actriia antagonists and uses for the treatment or prevention of breast cancer
EG25839A (en) Consolidating agent emulsions and associated methods
EP2019675A4 (en) METHODS FOR TREATING OR PREVENTING NEOPLASIA
EP1994181A4 (en) IDENTIFICATION AND USE OF NOVOPEPTIDES FOR THE TREATMENT OF CANCER
EP1981491A4 (en) COMPOSITIONS AND METHODS FOR TREATING OPHTHALMIC DROUGHT
PT2318033T (pt) Composições para o tratamento de dor e/ou inflamação
EP2084165A4 (en) PRO-DRUGS OF WATER-SOLUBLE OXICAMS POSITIVE AND RELATED COMPOUNDS WITH VERY HIGH SKIN PENETRATION SPEED
HK1162366A1 (en) Devices and methods for treating and or preventing diseases
EP2060264A4 (en) AGENT FOR TREATING OCULAR DISEASES
EP2214664A4 (en) BRCA1 BASED MEANS FOR THE PREVENTION OF MOM OR OVARIAN CARCINOMA AND METHOD OF ADMINISTRATION
ZA200901553B (en) Pest control agent in form of stable suspension
BRPI1011818A2 (pt) "método de tratamento de câncer com antagonista de dll4 e agente quimioterapêutico"
EP2046116A4 (en) HERBICIDE COMPOSITION AND METHOD OF USE
PL1863435T3 (pl) Zwiększone dostarczanie środków korzystnych dla skóry
GB0619262D0 (en) Compositions and methods for treating skin conditions
EP2430034A4 (en) 2'-FLUOR-ARABINO NUCLEOSIDES AND THEIR USE
IL200966A0 (en) Tetrahydroquinoline derivatives and the use thereof for the treatment of cancer
ZA200901452B (en) Treatment of vertigo with acetyl-L-leucine
EP2046118A4 (en) HERBICIDE COMPOSITION AND METHOD OF USE
IL207428A0 (en) Agents for treating and/or avoiding fire blight
EP2059621A4 (en) TEMPERATURE STABLE CAST ALLOY AND USE THEREOF
GB0613028D0 (en) Hair straightening iron with ionic treatment
EP2115464A4 (en) METHOD AND COMPOSITIONS FOR DETERMINING THE EFFECT OF BREAST CANCER THERAPEUTICS
GB0703634D0 (en) Treatment of white inorganic ores